Naratriptan Eg

Naratriptan, the active ingredient in Naratriptan Eg, is a Triptan (5‑HT1B/1D receptor agonist) presented as a oral tablet for oral use. It treats acute migraine attacks in adults. GNH USA supplies Naratriptan Eg as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan belongs to the Triptan class and is indicated for the acute treatment of migraine-related disorders. - Migraine: provides rapid relief of headache pain and associated symptoms when taken early in an attack. - Migraine with aura: alleviates headache and aura‑related discomfort during an acute episode. - Acute episodic migraine: aborts migraine attacks and reduces the need for additional medication.

Common Side Effects: - Nausea: mild to moderate stomach upset after dosing. - Dizziness: transient light‑headedness, especially when standing quickly. - Fatigue: feeling unusually tired or weak. - Dry mouth: reduced salivation causing throat discomfort. - Tingling or numbness: peripheral sensations in the hands or feet.

Serious or Rare Side Effects: - Chest discomfort or tightness: may indicate coronary vasospasm and requires immediate medical attention. - Serotonin syndrome: rare but potentially life‑threatening reaction when combined with other serotonergic agents. - Severe allergic reaction: rash, swelling, or difficulty breathing indicating anaphylaxis.

Before using Naratriptan, consider the following precautions: - Cardiovascular History: assess for coronary artery disease, uncontrolled hypertension, or cerebrovascular disorders. - Concomitant Medications: avoid other triptans, ergot alkaloids, or serotonergic drugs without medical guidance. - Allergies: confirm no hypersensitivity to naratriptan or any tablet excipients. - Pregnancy and Lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Driving and Machinery: exercise caution if dizziness or fatigue occurs after dosing. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Naratriptan may interact with several drug classes. Major Interactions (Avoid): - Other triptans: additive vasoconstrictive effects increase cardiovascular risk. - Ergot alkaloids: combined use can cause severe vasospasm. - Monoamine oxidase inhibitors (MAOIs): heightened risk of serotonin syndrome. Moderate Interactions (Monitor Closely): - SSRIs, SNRIs, or other serotonergic agents: monitor for signs of serotonin excess. - CYP1A2 inhibitors (e.g., fluvoxamine): may raise naratriptan plasma concentrations. - CYP3A4 inducers (e.g., carbamazepine): may reduce therapeutic effectiveness.